Biological
60 µg dose hepatitis B vaccine
60 µg dose hepatitis B vaccine is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_4
4
100%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 4Post-market surveillance
4(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 44 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
NCT03316807
completedphase_4
Immunogenicity of Hepatitis B Vaccination Among Drug Users
NCT02959775
completedphase_4
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
NCT02963714
completedphase_4
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
NCT02991599
Clinical Trials (4)
Showing 4 of 4 trials
NCT03316807Phase 4
Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
NCT02959775Phase 4
Immunogenicity of Hepatitis B Vaccination Among Drug Users
NCT02963714Phase 4
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
NCT02991599Phase 4
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4